Eliminate Coronary Artery Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02245087

Acronym

ECAD

Enrollment

Registered

2014-09-19

Start date

2014-08-31

Completion date

2019-09-30

Last updated

2022-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

atorvastatin, coronary artery disease, myocardial infarction, stroke, revascularization

Brief summary

The purpose of this study is to determine whether pharmacologic lowering of low density lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate or markedly reduce the composite endpoint of incident all cause mortality, myocardial infarction, stroke or coronary revascularization.

Interventions

DRUGAtorvastatin

20 mg of atorvastatin daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 59 Years

Healthy volunteers

Yes

Inclusion criteria

* Men 35-50 years of age * Women 45 - 59 years of age (must be sterile or \>2 years postmenopausal) * LDL cholesterol greater than 1.8 mmol/L (70 mg/dL) based on testing performed within 1 year * One risk factor for Coronary Heart Disease other than lipid abnormality: * Obesity and hypertension \[BP \>140 mmHg systolic and waist circumference \> 100 cm in men and \>90 cm in women\] * family history of premature myocardial infarction \[\<60 years\] * South Asian ethnic history * currently smoking

Exclusion criteria

* Currently taking cholesterol lowering medication * Qualify for cholesterol lowering medication based on current guidelines * Significant renal dysfunction (creatinine clearance \<30 ml/min) * Significant hepatic dysfunction (AST/ALT \>2.0 times upper limit of normal) * Active malignancy * Diabetes * Progressive or terminal illness, or other condition in which subject is unlikely to survive the study period * Known allergy, hypersensitivity (anaphylaxis) ar adverse reaction to any statin * Participation in a clinical trial (except observational studies) within previous 30 days * Received any investigation product within 30 days prior to participation in this clinical trial * Previously enrolled in this clinical trial

Design outcomes

Primary

Measure	Time frame
Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause in the follow up period	Up to 10 years

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026